Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

109.30EUR
1:36pm BST
Change (% chg)

€-5.80 (-5.04%)
Prev Close
€115.10
Open
€115.10
Day's High
€115.50
Day's Low
€109.20
Volume
127,769
Avg. Vol
101,517
52-wk High
€155.95
52-wk Low
€107.50

About

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes... (more)

Overall

Beta: 0.75
Market Cap(Mil.): €9,633.51
Shares Outstanding(Mil.): 83.66
Dividend: 0.85
Yield (%): 0.74

Financials

  IPN.PA Industry Sector
P/E (TTM): 44.34 29.30 32.55
EPS (TTM): 2.60 -- --
ROI: 11.19 14.23 13.83
ROE: 16.34 15.46 15.25

Trade tariff reprieve triggers relief in European shares

LONDON U.S. President Donald Trump's decision to delay an increase in tariffs on Chinese goods drove European shares to their highest since October with carmakers, most sensitive to the threat of a global trade war, leading the rally.

25 Feb 2019

Trade tariff reprieve triggers relief in European shares

LONDON U.S. President Donald Trump's decision to delay an increase in tariffs on Chinese goods drove European shares to their highest since October with carmakers, most sensitive to the threat of a global trade war, leading the rally.

25 Feb 2019

UPDATE 2-Trade tariff reprieve triggers relief in European shares

LONDON, Feb 25 U.S. President Donald Trump's decision to delay an increase in tariffs on Chinese goods drove European shares to their highest since October with carmakers, most sensitive to the threat of a global trade war, leading the rally.

25 Feb 2019

CORRECTED-UPDATE 1-Trade tariff reprieve triggers relief in European shares

LONDON, Feb 25 U.S. President Donald Trump's decision to delay an increase in tariffs on Chinese goods drove European shares to their highest since October as carmakers and mining companies rallied.

25 Feb 2019

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion (£1 billion), the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

25 Feb 2019

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

25 Feb 2019

UPDATE 2-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

* Takeover worth up to $1.31 billion (Adds share price reaction and analyst comment)

25 Feb 2019

RPT-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

25 Feb 2019

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

25 Feb 2019

French pharma group Ipsen closes in on its next drug deals

LONDON French drugmaker Ipsen plans to bring in multiple new medicines through a series of transactions and sees the recent price drop of biotech stocks as increasing deal opportunities, its chief executive said on Wednesday.

14 Nov 2018

Earnings vs. Estimates